SBIR/STTR Research Award
SBIR TOPIC 315: DEVELOPMENT OF COMPANION DIAGNOSTICS: ENABLING PRECISION MEDICINE
Award amount
$266,199Program and phase
SBIR · Phase IAward year
2013Award details
- Awarding agency
- Department of Health and Human Services
- Branch
- National Institutes of Health
- Recipient company
- ADAPTIVE BIOTECHNOLOGIES CORPORATION
- Proposal award date
- Not reported
- Contract end date
- Not reported
- UEI
- DMW5BNQ331K9
- Solicitation number
- Not reported
- Topic code
- NCI
Research abstract
Immunotherapy has emerged as a promising method to treat several cancers. In 2012 the FDA approved a new immunotherapy agent, ipilimumab, for metastatic melanoma. Ipilimumab activates T-cells and globally increases the adaptive immune response and resultsin an enhanced response to the cancer. In a subset of patients, this leads to longer Progression Free Survival (PFS), and in some cases remission. However, there is no companion diagnostic available to predict responders. The goal of this project is to develop a deep sequencing assay to measure the immune repertoire and a corresponding diagnostic protocol that differentiates ipilimumab responders from non-responders. Currently, while many of patients experience immune mediated side effects related to ipilimumab, less than 10% of patients cancer responds to therapy. Developing a companion diagnostic that differentiates responders from non-responders would protect non-responders from unnecessary side-effects. PUBLIC HEALTH RELEVANCE
Technology keywords
Not reported
Other awards by this recipient
Verified by the same UEI. These are other public SBIR/STTR award pages, not a merged company record.
- Correlating TCR diversity to immune reconstitution after cord blood transplant
- Non-invasive Diagnostic Platform Development for Celiac Disease Remission Status
- Minimal Residual Disease Monitoring by T-cell Receptor Repertoire Profiling
- Correlating TCR diversity to immune reconstitution after cord blood transplant
- Correlating TCR diversity to immune reconstitution after cord blood transplant
Awards with the same topic code
Verified by an exact topic code match. This is not a text-similarity match.
- Mini-reflectance confocal microscope (Mini-RCM) for aiding skin cancer diagnosis and treatment
- Development of small molecule therapeutics targeting AR-V7 for prostate cancer
- Decentralized Clinical Trial of Effectiveness of EnergyPoints App to Guide Acupressure Use for Fatigue and Sleep Disturbances in Cancer Survivors
- Optimized targeted radiotherapy of pancreatic cancer
- Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis
Research funding history
7 SBIR/STTR records share this UEI (2010–2017). Reported award amounts total $4,505,999. Reported amounts are not federal obligations.
Phases: Phase I, Phase II
Agencies: Department of Health and Human Services